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This study was undertaken to determine the highly sensitive method for detecting tumour lymphatic vessels in all the fields of each
slide (LV), lymphatic microvessel density (LMVD) and lymphatic vessel invasion (LVI) and to compare them with other prognostic
parameters using immunohistochemical staining with polyclonal (PCAB) and monoclonal antibodies (MCAB) to the lymphatic vessel
endothelial hyaluronan receptor-1 (LYVE-1), and the pan-endothelial marker factorVIII in a series of 67 human breast cancers. In all
LYVE-1-stained sections, LV (some of which contained red blood cells) were frequently found localised in extralobular stroma,
dermis, connective tissue stroma and adjacent to artery and vein, but were rare within the intralobular stroma or the tumour body
(3/67 cases) or areas of widespread invasion. In contrast small blood vessels were observed in intra- and extralobular stroma in the
factor VIII-stained sections. Quantitation of vessel numbers revealed that LYVE-1/PCAB detected a significantly larger number of LV
than either H&E or LYVE-1/MCAB (Po0.0001). LYVE-1/PCAB detected LVI in 25/67 cases (37.3%) and their presence was
significantly associated with both lymph node metastasis (w
2¼4.698, P¼0.0248) and unfavourable overall survival (OS) (P¼0.0453),
while not relapse- free survival (RFS) (P¼0.2948). LMVD had no influence for RFS and OS (P¼0.4879, P¼0.1463, respectively).
Our study demonstrates that immunohistochemistry with LYVE-1/PCAB is a highly sensitive method for detecting tumour LV/LVI in
breast cancer and LVI is a useful prognostic indicator for lymphatic tumour dissemination.
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The common pathways of cancer cell dissemination are via the
lymphatics and the bloodstream. It has been well established that
angiogenesis is necessary for tumour growth and haematogenous
metastasis (Weidner et al, 1991; Horak et al, 1992; Fox et al, 1995;
Kato et al, 2001). However, the role of the lymphatic system is less
understood. Some investigators have concluded that it is
impractical to distinguish between the blood and lymphatic vessel
systems as independent routes of tumour dissemination because
they are so interrelated (Fisher and Fisher, 1966). Our previous
studies challenge this by demonstrating that differences between
blood vessel invasion (BVI) and lymphatic vessel invasion (LVI) in
breast cancer can be distinguished by using antibodies against
factor VIII related antigen (Kato et al, 2002, 2003). However, the
distinction between lymphatic vessels and blood vessels was
sometimes difficult to determine and hence arbitrary. As yet there
have been no specific immunohistochemical markers available that
allow the identification of lymphatic vessels. Recent studies have
proposed a number of potential lymphatic-specific markers,
including the lymphatic vessel endothelial hyaluronan receptor-1
(LYVE-1) (Banerji et al, 1999; Jackson, 2004), Prox-1 (Wigle and
Oliver, 1999), podoplanin (Breiteneder-Geleff et al, 1997), and
vascular endothelial growth factor receptor-3 (VEGFR-3) (Kukk
et al, 1996; Lymboussaki et al, 1999; Jackson, 2001) and D2-40
(Kahn et al, 2002).
There has been debate in the literature as to whether lymphatic
vessels exist within tumours (Leu et al, 2000; Nathanson et al,
2000; Padera et al, 2000; Birner et al, 2001; Mandriota et al, 2001;
Schoppmann et al, 2001; Skobe et al, 2001; Stacker et al, 2001;
Beasley et al, 2002; Dadras et al, 2003; Hall et al, 2003; Maula et al,
2003; Straume et al, 2003; Williams et al, 2003); whether tumours
induce lymphangiogenesis (Leu et al, 2000; Nathanson et al, 2000;
Sleeman, 2000; Mandriota et al, 2001; Schoppmann et al, 2001;
Skobe et al, 2001; Stacker et al, 2001; Beasley et al, 2002; Williams
et al, 2003); whether lymphangiogenesis or dilated pre-existing
lymphatic vessels increase the probability of lymphatic tumour
dissemination (Leu et al, 2000; Padera et al, 2000; Sleeman, 2000;
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and whether cancer cells require active intravasation (Hartveit,
1990; Gunningham et al, 2000; Kinoshita et al, 2001; Schoppmann
et al, 2001).
In this study, we used both polyclonal and monoclonal
antibodies to the lymphatic-specific marker LYVE-1, a homologue
of the CD44 hyaluronan receptor (Banerji et al, 1999; Jackson,
2003; Jackson, 2004) to identify lymphatic vessels in breast
tumours. In parallel, we also looked at haematoxylin and eosin
(H&E) and factor VIII-related antigen staining (FVIII). We
determined the presence and distribution of lymphatic vessels
and examined the relationships of LVI and lymph-node metastases
in a retrospective series of 67 human breast carcinomas.
PATIENTS AND METHODS
Tumour collection
In all, 67 consecutive unselected patients who underwent breast
cancer surgery at the Tokyo Women’s Medical University Hospital
between January 1991 and December 1991 were included in the
present study. To be included, the patients (all female) had to have
primary, unilateral, breast cancer and no other malignancy.
Clinical and pathological data are listed in Table 1. Estrogen and
progesterone receptor (ER and PR) content were determined
biochemically using the dextran-coated charcoal (DCC) method.
Tumours were classified as estrogen receptor or progesterone
receptor-positive if the content exceeded 5fmolmg
 1.
Immunocytochemical techniques
Serial sections were prepared from representative formalin-fixed
and paraffin-embedded tissue blocks from this series of breast
cancer. Tissue samples of 5mm thick sections stained with
haematoxylin and eosin (H&E) were assessed histopathologically
and were used to select the maximal area of all the cut surfaces of
the tumour that included the invasive components. Immunostains
for FVIII-related antigen were performed on paraffin sections
using the streptavidin-biotin-immunoperoxidase method as pre-
viously described (Kato et al, 2002, 2003). Briefly, formalin-fixed,
paraffin-embedded sections were dewaxed in 100% Citroclear,
rehydrated through graded 100% industrial methylated spirit
(IMS) series, and immunostaining was performed using a
polyclonal antibody (von Willebrand factor, Dako, Copenhagen,
Denmark) applied at 1:200 for 1h at room temperature. Technical
details of the polyclonal and monoclonal LYVE-1 staining are
outlined in Tables 2 and 3. A normal human tonsil served as a
Table 1 Clinicopathologic characteristics of 67 patients
Characteristics No. of patients (%)
Patients enrolled 67
Age (years)
Median 49
Range 30–86
Menopausal status
Pre 36 (53.7)
Post 31 (46.3)
Clinical tumor size, T
T1 26 (38.8)
T2 34 (50.7)
T3 7 (10.5)
Lymph-node status
Negative 43 (64.2)
Positive 20 (29.9)
Unknown 4 (5.9)
ER
Negative 29 (43.3)
Positive 35 (52.2)
Unknown 3 (4.5)
PR
Negative 38 (56.7)
Positive 26 (38.8)
Unknown 3 (4.5)
Histological classification
Noninvasive ductal carcinoma 5 (7.5)
Infiltrating ductal carcinoma 57 (85.0)
Infiltrating lobular carcinoma 1 (1.5)
Others 4 (6.0)
ER¼estrogen receptor; PR¼progesteron receptor.
Table 2 The method for polyclonal antibody against LYVE antigen
1 Deparaffinise sections in 100% citroclear for 10min
2 Rehydrate through graded 100% industrial methlated spirits (IMS)
series for 5min
3 Predigest with 0.1% Protease for 5min
4 Abolish endogenous peroxidase activity with 3% hydrogen
peroxide for 20min
5 Leave slides to tap water for 5min
6 Wash in phosphorate-buffered saline (PBS, pH 7.0)
7 Suppress nonspecific background staining with 5% normal human
serum for 15min
8 Apply primary antibody (1:600 diluted LYVE-I polyclonal antibody
in PBS) for 1h at room temperature
9 Wash in PBS for 5min
10 Apply secondary antibody (DAKO anti-rabbit envision HRP
polymer) for 30min at room temperature
11 Wash in PBS for 5min
12 Apply 0.05% 3,30-diaminobenzidine tetrahydrochloride (DAB)
substrate provided in envision kit for 4min
13 Wash in distilled water
14 Counter-staining by hematoxylin
15 Aquamount
LYVE: lymphatic vessel endothelial hyaluronan receptor-1.
Table 3 The method for monoclonal antibody against LYVE antigen
1 Deparaffinise sections in 100% citroclear for 10min
2 Rehydrate through graded 100% industrial methlated spirits (IMS) series
for 5min
3 Antigen retrieve; microwave in Dako target antigen retrieval buffer
diluted 1:10 at 95–1001C for 40min
4 Wash in water, rinse distilled water, then transfer tris-buffered saline
(TBS)
5 Abolish endogenous peroxidase activity with peroxidase block from
Dako envision kit for 5min
6 Wash in TBS for 5min
7 Apply primary antibody (LYVE-I monoclonal antibody diluted 1:2 with
0.1% bovine serum albumin in TBS) at 41C over night
8 Wash in TBS for 5min
9 Apply secondary antibody (DAKO anti-mouse envision HRP polymer)
for 30min at room temperature
10 Wash in TBS for 5min
11 Apply 0.05% 3,30-diaminobenzidine tetrahydrochloride (DAB)
substrate provided in envision kit for 5min
12 Wash in TBS, rinse distilled water
13 Counter-staining by hematoxylin
14 Aquamount
LYVE¼lymphatic vessel endothelial hyaluronan receptor-1.
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clonal antibody to LYVE-1 (LYVE-1/PCAB and LYVE-1/MCAB)
were generated as described previously (Banerji et al, 1999; Cao
et al, 2004).
Assessment of lymphatic vessels
H&E staining We defined as lymphatics those vessels lined by
flattened endothelial cells, in the presence or absence of lympho-
cytes and absence of erythrocytes, in the stroma or adjacent to
arteries and veins.
LYVE-1/PCAB. staining and LYVE-1/MCAB staining Positive
vessels were scored as lymphatic vessels. Staining intensity was
assessed as follows; strong staining; moderate staining; weak
staining (Figure 1A and B).
Counting of lymphatic vessels and determination of
lymphatic microvessel density (LMVD) and blood
microvessel density (BMVD)
Both the number and intensity of staining of the lymphatic vessels
were evaluated. The intensity of staining and level of tissue
damage were expressed as weak, moderate and strong. We defined
as a lymphatic vessel the vessel, which have endothelium with
immunopositivity and a vascular lumen. Mean lymphatic vessel
count was determined by averaging the number of total lymphatic
vessels in all the fields of each slide, including within the tumour
or at the periphery of the tumour, at  100 or  200 magnifica-
tion. Single brown-stained endothelial cells with a lumen were
counted as individual lymphatic vessels, as shown in Figure 1C.
The three most vascularised areas (‘hot spots’) were selected at
low power magnification ( 40) and LMVD and BMVD were then
determined by counting all LYVE-1/PCAB-immunostained or
factor VIII related antigen stained vessels at  200 magnification.
When the average number was higher than the median number of
LYVE-1/PCAB or FVIII related antigen positive vessels, the cancer
was considered to have a high LMVD or BMVD, otherwise a low
LMVD or BMVD.
Statistical analysis
Statistical analysis of the data was performed with the Survival
Tools for Statview-J 5.0. package (Abacus Concepts, Berkeley, CA,
USA). For comparison of number of lymphatic vessel assessed
by the three different staining methods, for association of LMVD
and clinical or pathologic parameters and for the association of
LVI and lymph-node status, Kruskal–Wallis test, Mann–Whitney
U-test and w
2 test were used. The association of the numbers of
lymphatic vessels in the LYVE-1/PCAB and those in LYVE-1/
MCAB stained sections was assessed by Pearson’s correlation
coefficient. We examined the univariate relationships between
prognostic indicators and relapse-free survival (RFS) and overall
survival (OS) by fitting Kaplan–Meier survival curves (Kaplan and
Meier, 1958) to various levels of the prognostic indicators.
RESULTS
Both the polyclonal and monoclonal anti LYVE-1 antibodies
yielded specific and consistent staining of endothelial cells in the
lymphatic vessels (Figure 1A and B). Many lymphatic vessels were
frequently detected in dermis, connective tissue stroma (Figure 1A
and B), retro-mammary tissue, adjacent to artery and vein and
extralobular stroma (Figure 1C). However, lymphatic vessels were
rarely seen in intralobular stroma (Figure 1C), intra-tumour tissue,
areas of necrosis, adipose tissue (Figure 1A and B) and muscle. In
contrast, in the FVIII-stained sections small blood vessels were
observed in both intra- and extralobular stroma (Figure 1D).
In addition to those findings many lymphatic vessels, which
contained red blood cells were observed in H&E, FVIII staining,
LYVE-1/PCAB and LYVE-1/MCAB-stained sections. (Figure
1E–H). It was difficult to distinguish between lymphatic
vessels and blood vessels by the finding of the presence or
absence of erythrocytes in the lumen of vessels detected by H&E
staining alone.
The mean and median (range) number of all lymphatic vessels is
shown in Table 4. The total and the mean number of LYVE-1/
PCAB-immunostained lymphatic vessels were higher than that
of the H&E and LYVE-1/MCAB- stained lymphatic vessels.
(Po0.0001). Strong significant correlation was between the
LYVE-1/PCAB-immunostained lymphatic vessels and LYVE-1/
MCAB-immunostained lymphatic vessels (Pearson’s correlation
coefficient¼0.815, Po0.0001). Median LMVD was 6.1micro-
vesselsmm
 2 (range 0–17.9 vessels). A strong significant correla-
tion was found between LMVD and LYVE-1/PCAB-immunostained
lymphatic vessels (Pearson’s correlation coefficient¼0.718,
Po0.0001). There was no significant correlation between the
LMVD and BMVD (Pearson’s correlation coefficient¼0.021,
P¼0.8710). An inverse correlation was seen between histological
grading and LMVD (P¼0.0434), while histological grading or
menopausal status trended with the number of lymphatic vessels
(P¼0.0712) or LMVD (P¼0.0944). There was no significant
correlation between clinical tumour size, lymph-node status, LVI,
or estrogen receptor and LMVD or the mean number of lymphatic
vessels (Table 5). LVI was detected by H&E, LYVE-1/PCAB and
LYVE-1/MCAB staining in 23/67 cases (34.3%), 25/67 cases
(37.3%) and 20/67 cases (29.9%), respectively. The lymph-node
status or LVI detected by H&E, LYVE-1/PCAB and LYVE-1/MCAB
was not associated with the mean number of lymphatic vessels
(P¼0.6413, P¼0.8339, P¼0.8884 or P¼0.7412, P¼0.5759;
P¼0.8075, respectively), but LVI detected by LYVE-1/PCAB was
significantly associated with lymph-node status (w
2¼4.698,
P¼0.0248, Table 6). A significant difference in OS was found
between patients with LVI or without LVI (P¼0.0453), while no
significant difference in RFS (P¼0.2948). However, LMVD had no
influence for OS and RFS (P¼0.4879, P¼0.1463, respectively).
DISCUSSION
This manuscript has focused on the utility of different LYVE-1
antibodies as routine markers for detecting and quantitating
lymphatic vessels in breast cancer. Our results confirm that both
LYVE-1 polyclonal and monoclonal antibodies distinguish effi-
ciently between lymphatic and blood vessels in pathological
specimens. However, due to the greater dependence of LYVE-1
monoclonal antibodies on tissue fixation and antigen retrieval
methods that result in partial antigen destruction, we have
found that LYVE-1 polyclonal antibodies are suited to routine
immunohistochemical staining applications. Furthermore,
using immunohistochemical staining with LYVE-1 polyclonal
antibodies we have shown that lymphatic invasion is positively
associated with lymph node involvement and unfavorable OS.
Quantitation of tumour lymphatic vessels for the purpose of
tumour staging has for decades been problematic. Although
morphology can sometimes distinguish lymphatic vessels from
blood vessels by the frequent absence of a basement membrane
and lack of erythrocytes in the latter, neither is a reliable method
for routine use. These considerations have hampered the reliable
identification of tumour lymphatic vessels in routine histopatho-
logy. More recently, however, the development of specific markers
such as the lymphatic hyaluronan receptor LYVE-1, the subject of
this manuscript, has allowed many new experimental studies of
tumour lymphatics to be initiated. To date, the majority of these
studies have employed LYVE-1 polyclonal antibodies, requiring
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sFigure 1 (A) Several LYVE-1/PCAB-positive lymphatic vessels are present in the connective tissue stroma (A: LYVE-1/PCAB staining, haematoxylin
counter stain). (B) The monoclonal anti LYVE-1 antibodies (LYVE-1/PCAB) yielded specific and consistent staining of endothelial cells in the lymphatic
vessels (B: LYVE-1/MCAB staining, haematoxylin counter stain). (C) The arrows indicate lymphatic vessels, which are detected by LYVE-1/PCAB staining.
We found nine lymphatic vessels in this field. Lymphatics are frequently found in extralobular stroma, but rarely seen in intralobular stroma. Blood vessels
(arrowheads) are not stained by the staining (C: LYVE-1/PCAB staining, haematoxylin counter stain). (D) The arrowheads show blood vessels, which are
stained by factor VIII related antigen staining. They are found in both intra- and extralobular stroma. The intensity of endothelial cells in the lymphatic vessels
(arrows) in factor VIII related antigen-stained section is very faint, discontinuous and inconsistent (D: factor VIII-related antigen staining, haematoxylin counter
stain). (E, F, G and H) Serial sections were prepared for 4 kinds of staining. Some lymphatic vessels (arrows), which contained red blood cells, were
observed in haematoxylin and eosin (H&E), factor VIII related antigen, LYVE-1/PCAB and LYVE-1/MCAB-stained sections. Arrows indicate lymphatic vessels
and arrowheads show blood vessels (E: H&E staining; F: factor VIII related antigen staining; G: LYVE-1/PCAB staining; H: LYVE-1/MCAB staining,
haematoxylin counter stain). (I) A lymphatic vessel with floating tumour cells (LVI) was found localised in the connective tissue stroma (I: LYVE-1/PCAB
staining, haematoxylin counter stain).
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smicrowave treatment or pressure cooking for antigen retrieval
(Banerji et al, 1999; Beasley et al, 2002; Williams et al, 2003). In
this present manuscript, we found that the intensity of many
endothelial cells in the lymphatic vessels of either microwave or
pressure cooking treatment stained with LYVE-1/PCAB was
similar to that seen with protease retrieved tissue sections.
However, some breast tissue sections in the former treatment
were damaged, so it was difficult to observe the lymphatic vessels
of all the fields in each slide. These results confirm that proteolytic
enzyme treatment for LYVE-1/PCAB staining as well as for FVIII
staining is more useful than either microwave or pressure cooking
treatment in the human breast tissue. The LYVE-1/MCAB requires
the use of microwave antigen retrieval to produce good staining
without background. The staining of lymphatic vessels in LYVE-1/
MCAB–stained sections was occasionally more intense than that
in LYVE-1/PCAB–stained sections (Figure 1A and B). However,
because of the use of microwave antigen retrieval, section quality is
often low so that the estimation of the total number of lymphatic
vessels is less reliable than with LYVE-1/PCAB staining.
Previous studies have reported that all blood vessels that contain
erythrocytes are negative for LYVE-1 supporting its specificity for
lymphatics (Banerji et al, 1999; Williams et al, 2003). However, in
this study, we observed some LYVE-1-positive vessels containing
erythrocytes in both LYVE-1/PCAB and LYVE-1/MCAB-stained
sections (Figure 1E–H). A prominent function of the lymphatic
system is the provision of fluid drainage of lymphocytes, protein,
colloid and foreign antigens from the tissues to the peripheral
lymph nodes. Moreover lymphatic vessels act as a conduit for both
migrating inflammatory cells and possibly erythrocytes from
inflammatory tissue and parenchyma or stroma with haemorrhage.
Hartveit has described tumour cells in the periductal lymphatic
spaces being washed with the tide of interstitial fluid into the
lymphatic network and into the lymphatic vessels (Hartveit, 1990).
Therefore lymphatic vessels containing erythrocytes may well
be observed from time to time especially in tumours. Based on
similar findings in tumours by Padera the specificity of LYVE-1
for lymphatics has recently been questioned. This can be
explained either by the presence of haemovascular-lymphovascu-
lar shunts (Clarijs et al, 2001; Abtahian et al, 2003), by leakiness
of newly proliferating tumour blood capillaries that is high
degree of fenestration, or rupture giving rise to RBC that enter
the lymphatic vessels. It is possible that there are more of these
in tumours further explaining our findings of erythrocytes in
LYVE-1 positive vessels.
Several recent studies in animal models have reported that
lymphatic vessels are frequently observed in the peripheral rim of
the tumour, but not in the body of the tumour itself (Leu et al,
2000; Padera et al, 2000). However, others demonstrated the
existence of intratumoural lymphatic vessels, in xenotransplanted
breast tumours and fibrosarcomas in mice and in human head and
neck cancers respectively (Skobe et al, 2001; Stacker et al, 2001;
Beasley et al, 2002; Jackson, 2004). Most studies in human breast
cancer described a similar peritumoural distribution (Nathanson
et al, 2000; Schoppmann et al, 2001; Williams et al, 2003; Bono
et al, 2004) which is largely supported by the current study which
Figure 1 Continued.
Table 4 Comparison of the three methods for detection of lymphatic
vessels
Methods of staining H&E
LYVE-1/
PCAB
LYVE-1/
MCAB P-value
Number of lymphatic vessels
Total number
of 67 cases
4274 17334 10919
Mean7s.d. 63.8764.4 258.77219.1 163.07155.7 o0.0001
Median 45 204 109
Range 4–372 0–828 2–575
Level of expression
(No. of patients)
Weak 19 (28.4%) 25 (37.3%)
Moderate 19 (28.4%) 25 (37.3%)
Strong 29 (43.2%) 17 (25.4%)
Level of tissue damage
(No. of patients)
Weak 59 (88.1%) 5 (7.5%)
Moderate 8 (11.9%) 48 (71.6%)
Strong 0 14 (20.9%)
H&E¼hematoxylin and eosin; LYVE-1¼lymphatic vessel endothelial hyaluronan
receptor-1; PCAB¼polyclonal antibody; MCAB¼monoclonal antibody.
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sshows that lymphatic vessels are frequently found in the
extralobular stroma and connective tissue stroma (Figure 1A–C)
but are rarely seen in the intralobular stroma and within the
tumour itself. The reasons for this selective localisation of
lymphatic vessels in tumours is unknown but one possibility is
that they are collapsed in expanding tumours because of the high
interstitial pressure. That would suggest that they are present, but
difficult to detect because of their flattened morphology. In any
case ‘collapsed’ is a subjective interpretation of appearance in
histological sections. Even presumably fully functional lymphatic
vessel in normal tissue can look ‘collapsed’. The growth of tumour
lymphatics is likely to be limited by availability of lymphangio-
genic growth factors, related to infiltration by tumour associated
macrophages (Williams et al, 2003), physical barriers to intra-
tumoural lymphatic vessel growth (Mandriota et al, 2001) or
inhibitory mechanisms as yet undefined, but perhaps similar to
those that appear to prevent lymphatic vessel growth in the cornea
(Cursiefen et al, 2002). Those lymphatic vessels which are present
at the tumour periphery are considered to be pre-existing
lymphatics rather than those induced by tumour lymphangio-
genetic factors (Leu et al, 2000).
Recent studies have demonstrated that VEGFR-3 or D2-40
immunostained microvessels was associated with either node
metastases (Nathanson et al, 2000) or BMVD (Choi et al, 2005) and
a high peritumoural lymphatic vessel density is associated with
a poor outcome in human breast cancer (Bono et al, 2004). On
the other hand, other researchers reported that there was no
significant correlation between LMVD and BMVD (Schoppmann
et al, 2001; Bono et al, 2004), tumour size, histological grading or
nodal status (Williams et al, 2003) and no significant difference
between high lymphatic vessel density and low one for RFS and OS
(Schoppmann et al, 2004). The results of our study suggest that
an inverse correlation was seen between LMVD and histological
grading, while there was no significant correlation between LMVD
and lymph-node status or LVI and LMVD was not associated with
a poor outcome. As there was no significant correlation between
LMVD and BMVD, the genesis of lymphatic vessels might be
different from that of blood vessels (Schoppmann et al, 2001). It is
tempting to speculate that as lymphatics in tumour with increased
aggressiveness could be excluded and destroyed by cancer
(Williams et al, 2003), LMVD has no influence for lymphatic
tumour dissemination.
The current study has used LYVE-1 staining to increase the
accuracy and rate of detection of LVI since using this method
makes it easy to distinguish from BVI (Figure 1I). In recent human
studies the rate of LVI fell to within the range of 13.3 and 53.3%
(Schoppmann et al, 2001; Williams et al, 2003), while the rate of
Table 5 Association of LMVD and other clinical and pathologic parameters
No. of patients (%) Mean LMVD P-value Mean LV P-value
Patients enrolled 67 6.374.2 258.77219.1
Clinical tumor size, T 0.3061 0.5812
T1 26 (38.8) 7.374.6 277.17219.0
T2 34 (50.7) 5.873.9 258.47228.6
T3 7 (10.5) 4.773.5 191.57184.4
Histological grading, HG 0.0434 0.0712
HG1 21 (31.4) 6.573.1 287.37200.1
HG2 24 (35.8) 7.674.8 307.17252.8
HG3 22 (32.8) 4.673.9 178.57180.1
Lymph-node status 0.8305 0.4764
Negative 43 (64.2) 6.474.1 254.27213.1
Positive 20 (29.9) 6.374.5 242.47188.9
Unknown 4 (5.9) 4.872.9 342.27351.2
Lymphatic vessel invasion 0.525 0.3088
Negative 42 (62.7) 5.973.8 231.17197.6
Positive 25 (37.3) 6.874.8 305.07248.4
Menopausal status 0.0944 0.1609
Pre 36 (53.7) 6.974.1 287.17205.5
Post 31 (46.3) 5.574.2 225.77232.9
Estrogen receptor 0.691 0.8451
Negative 29 (43.3) 5.874.0 257.37208.8
Positive 35 (52.2) 6.674.4 267.17235.4
Unknown 3 (4.5) 7.274.6 174.07140.8
LMVD¼lympatic microvessel density; LV¼the number of total lymphatic vessels in all the fields of each slide.
Table 6 Association of LVI detected by three kinds of staining and
lymph-node status
Lymph-node statusc
Negative Positive
Methods of
staining
No. of
patients
No. of
patients (%)
No. of
patients (%) P-value
LVI/H&E 0.1293
Negative 40 30 (75.0) 10 (25.0)
Positive 23 13 (56.5) 10 (43.5)
LVI/LYVE-1/PCAB 0.0146
Negative 39 31 (79.5) 8 (20.5)
Positive 24 12 (50.0) 12 (50.0)
LVI/LYVE-1/MCAB 0.2457
Negative 44 32 (72.7) 12 (27.3)
Positive 19 11 (57.9) 8 (42.1)
LVI¼lymphatic vessel invasion; H&E¼hematoxylin and eosin; LYVE-1¼lymphatic
vessel endothelial hyaluronan receptor-1; PCAB¼polyclonal antibody;
MCAB¼monoclonal antibody. Four cases with unknown lymph-node status were
excluded.
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sLVI detected by LYVE-I/PCAB staining was seen in 25/67 cases
(37.3%) in this study, and the potential importance of measuring
the LVI is that it has been strongly associated with the presence of
lymph-node metastases and unfavorable OS in human breast
cancer (Schoppmann et al, 2004). The results in this present study
support that suggestion.
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